The aim of this article is to sum up all the relevant DueDiligence of the company in one single article. After discussing the value of each drug in the pipeline and giving them the fair value they deserve, we come to the conclusion that BCRX should currently be valued at $184.77. If you are looking for some extensive and detailed DD on the company, i think this is the article you look for, and I highly suggest you keep reading it. In case you find the given information useful, i encourage you to support the article in order to reach more people and rise awareness of how undervalued BCRX is. submitted by PitBullTrades to WallStreetbetsELITE [link] [comments] If you want to dig deeper, check out u/bio9999 and the community BCRX, some of the informartion related with Galidesivir directly come from bio9999's posts.
https://preview.redd.it/h14qnmmii1g61.png?width=352&format=png&auto=webp&s=3be0a507d364bdbeeb4c4a9a2e781890858902f6
What makes Jon Stonehouse a unique CEO is the dedication he has towards patients through his commitment to working faster in order to bring life-saving rare disease therapeutics to patient populations around the world. His passion is further substantiated by the note he had pasted on his monitor during the 2021 JPM Healthcare Conference https://preview.redd.it/9f8th8iji1g61.png?width=712&format=png&auto=webp&s=eb8376b619942b56af61eec34bde9262ecdcc19c
https://preview.redd.it/wf23vakki1g61.png?width=1305&format=png&auto=webp&s=2fc25facdf792148c474d72a1e923318456e326c What should catch investors attention is Alex Denner, head of Sarissa Capital Management recently increasing his stake in the company, managing to own 5% of it. He is one of the most well known biotech investors in the industry. He is the largest inside shareholder of Biogen pharma, ticker BIIB, and notorious for not only finding incredibly deep value in preclinical companies, but for being an "active" vs passive role in their success. After taking large positions in his value finds, he becomes an advocate for high level decisions from management that unlock shareholder value. He speaks up against possible bad M&A deals and has been known to bring two companies together to facilitate other deals.
○ Orladeyo ™ (berotralstat) oral pill Orladeyo is the first Oral approved treatment used to prevent swelling attacks in people with hereditary angioedema (HAE), disease which is estimated to affect 1 in 50,000 people. Berotralstat is currently approved in two countries, on December the 3rd it got approved by the FDA in USA, and on January the 22nd in Japan. The company expects approval of Orladeyo in Europe to happen early Q2. Before oral Orladeyo was approved for HAE, patients would only have treatments that required usage of needles. This dramatically reduced the quality of their life, making some of them quit using the treatment. That's the main reason why Orladeyo is a game changer. After the approval, surveys on patients were done, showing a large number of new patients that were not treated before due to needles, now willing to be treated taking oral form Orladeyo pills. https://preview.redd.it/iuh6qnrli1g61.jpg?width=1080&format=pjpg&auto=webp&s=5228ca462d8e56709a8b5ddde1a5c0c6c10b4d71 As it's shown in the page 13th of the January 2021 Corporate Presentation (page 13), in their recently undergone survey, 59% of the patients expressed high willingness to use Orladeyo, and that number rised to 71% with Physician recommendation. https://preview.redd.it/m7fffvomi1g61.png?width=1274&format=png&auto=webp&s=1facd08901d25f90de1a74b7e966d9503a748859 Additional surveys were undergone on patients using treatments from the competence "Cynrize, Haegarda, Takhzyro" and the results were the following ones (page 14). https://preview.redd.it/utqjd8lni1g61.png?width=1274&format=png&auto=webp&s=bb6c59ce6f26fce2301d9bf2b0a47fc1fc4164e0 Number of Patients USA In the USA there are 10,000 patients, 7500 diagnosed and treated, 1700 diagnosed but not treated, 600 treated but not diagnosed. Physicians expect to prescribe Orladeyo for over 41% of HAE patients. Conservatively thinking, taking 7,500 patients out of the total 10,000 pool in the USA, with over 41% of patients prescription ( page 16 ) we would conservatively aim for 3,075 patients. Japan On November the 5th Biocryst undergone an agreement with Torii Pharmaceuticals. A local Japanese company that will be in charge of getting new patients to be treated with Orladeyo in Japan and commerzialing it. After Orladeyo received the approval in Japan, Goichi Matsuda, president of Torii said the following words "Until now, HAE patients in Japan had no therapies approved to prevent attacks, so the approval of Orladeyo marks a significant advance in HAE treatment", "We are pleased to have the opportunity to bring the first oral treatment option to Japanese HAE patients and are actively preparing for the commercialization". Japan has 2,500 HAE patients, and Biocryst conservatively expects to at least reach 500 patients this year. Europe It's estimated to be around 12,000 HAE patients in Europe. Following the physician prescription of over 41% of patients to prescribe (page 16) for Orladeyo. We get a total of 4,920 patients in Europe Pricings/Revenue Each patient will have to pay 485K/year to access the drug in USA. In Japan and Europe the pricing system changes since pricing and jurisdictions work in a different way there. Making it 200K/year. With this yearly prices and the amount of patients defined before, we get the following results. 3,075 x 485K = 1,491,375,000$ 500 x 200K = 100,000,000$ 4,920 x 200K = 984,000,000$ Summing it all up we get 2,575,375,000$. From that number we have to subtract 74,625,000$ making it a total of 2,500,750,000$. The sustraction happens as a result of the undergone Royalty agreements with Torii Pharmaceuticals and Royalty Pharma. In the following link, you will have access to a google sheet, where yearly revenues generated by Orladeyo is estimated. A wide range of multipliers regarding the total patient pool that Orladeyo could capture is added, ranging from ( 10%, 20%, 41% and 75%).Revenues have been estimated with the actual price of Orladeyo in 2021 485K/year, it also has an estimation looking forward to 2025, on how the price of the drug will rise due to inflation. Finally there is a chart that gives an idea of what the the market cap could reach to be using revenue multipliers. Orladeyo value Having in mind the discussed numbers before, Orladeyo alone will be generating 2,500,750,000$ a year, using the average mid-cap Biotech company multiplier x7. We get a total of 17,505,250,000$, meaning an increase of 99.40$ in the stock price. https://preview.redd.it/rk2jrdpoi1g61.png?width=1403&format=png&auto=webp&s=02ebca8ee2255345dbf8cf4f02f092746398f66b Orladeyo value: 99.40$ SP ○ Peramivir ™ (Rapivab) Peramivir (Rapivab) is an antiviral drug for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration. On 19 December 2014, the FDA approved Peramivir to treat influenza infection in adults. Peramivir has also been approved in Japan and South Korea and is available in Japan as Rapiacta and in South Korea as Peramiflu. The U.S. government (department of Health and Human Services) gave BioCryst Pharmaceuticals more than $77 million to finish the Phase III clinical development of peramivir. In 2009 the department of Health and Human Services had already given about $180 million to the program. In 2013 the Biomedical Advanced Research and Development Authority (BARDA/HHS) released new funding under the current $234.8 million contract to enable completion of a New Drug Application filing for intravenous (IV) peramivir. Rapivab is a bio-defense drug that is often stockpiled by the government. Last time being September the 26th, with a purchase of $14 million. Peramivir value With all the explanations given above and having in mind Peramivir is a government bio-defense drug the value of Rapivab can not be less than $750,000,000 conservatively speaking. https://preview.redd.it/g3xkfbjpi1g61.png?width=900&format=png&auto=webp&s=677f4881c4c1ec1b223a393356d826ef994cd59d
○ Galidesivir - BCX4430 The NIAID and BARDA have been funding the development and testing of Galidesivir for over 15 years as they recognize its importance in preparation for all future pandemics. Recently, the 31st of August, 2020 NIAID Awarded $44 Million Contract to Advance Development of Galidesivir. Besides COVID-19, the world suffers from 200 million infections per year from filoviruses (Ebola, Marburg), flaviviruses (Hepatitis C, West Nile, Dengue, Jap Encephalitis, Yellow Fever, TBEV, OHFV, and Zika), arenaviruses, bunyaviruses, orthomyxoviruses, picornaviruses and paramyxoviruses (think RSV). Galidesivir is the first antiviral that has ever shown such potential, and to top it off, it is now known from the Phase I trial and now the Brazil part 1 trial to clearly be safe and show dose-sensitive effects in people. And based on multiple animal studies, it works equally effectively as a pill that is stable for years at room temperature. Not only that, but this antiviral, unlike any of the others, has excellent penetration of the blood brain barrier as was seen in the macaque Zika virus study. Efficacy Phase I safety trials in humans had shown that it was safe and well tolerated .NIAID on April 9th 2020 its expansion of the Brazilian yellow fever trial to include three cohorts of 8 severely affected COVID-19 patients, each being given a different IV dose regimen . Unfortunately, but obvious in hindsight, this trial was from the beginning underpowered to determine a clinical benefit. The patients were followed for eight weeks after their treatments. The company on December 22nd announced that all three doses were perfectly safe for the patients. In addition, they found that patients had a dose-sensitive reduction in virus levels in their lungs. They went on to say that an animal model, which will likely be published shortly, showed that Galidesivir significantly reduced COVID-19-associated lung damage. Despite all this and even though the trial was not even powered to detect a clinical difference in the patients, the NIAID, after finding an insignificant difference in outcomes between the small numbers of drug-treated and placebo-treated patients, inexplicably decided to discontinue clinical trials of it for COVID-19, to the great confused dismay of investors and perhaps even taken advantage of by short hedge funds who brought the stock down in late December. Bear in mind that during this trial, one of the most lethal strains of COVID-19 we know of was affecting the Brazilian trial sites, later known now as the P.1 or Manaus strain, and could have easily negatively affected the clinical outcomes of this small trial too given that the trial was focused on very sick patients more likely to carry this bad strain. Galidesivir value First of all, we must have in mind that Galidesivir is a Government funded bio-defense drug, that aims to treat a wide range of viruses as explained before. Its global stockpiling for future pandemics is also an absolute certainty given its long-term stability. With all the explanations being given, conservatively talking Galidesivir can not be worth less than $2.5B, this is 14.20$. https://preview.redd.it/la3l2rcqi1g61.png?width=1014&format=png&auto=webp&s=e7ad9c62790d7480afff31cfc35c4731ec86e078
○ FOP - BCX9250 FOP is an ultra-rare, severely disabling condition characterized by the irregular formation of bone outside the normal skeleton, also known as heterotopic ossification (HO). HO can occur in muscles, tendons and soft tissue. Patients with FOP become bound by this irregular ossification over time, with restricted movement and fused joints, resulting in deformities and premature mortality. There are currently no approved treatments for FOP. There are an estimated 3,500 to 9,000 patients worldwide, with 900 diagnosed so far. Currently there aren’t any approved treatments. Market size for this treatment is estimated to reach 500M-900M in 2025, growing to 3B in 2028 as more patients are diagnosed. With a price ranging from $900K-$1M/year. Last December the 21st Biocryst announced positive Phase 1 results “BCX9250 was safe and well tolerated at all doses studied, with linear and dose-proportional exposure supporting once-daily dosing.”. “In preclinical studies, BCX9250 demonstrated potency for the target kinase, selectivity, safety and strong suppression of HO in animal models.” BCX9250 Value BCX9250 study will most likely take 4 years to finish, this is, until 2025. By then the potential market we will be aimming for, will be $750,000,000 aprox. Drugs that are in Phase 1 studies are said to have a 10% chance of making it to the market. Following that, BCX9250 as of now shuld be valued at $75,000,000 = 0.426$ https://preview.redd.it/xv4s7d8ri1g61.png?width=1256&format=png&auto=webp&s=63c2574e418ec445ceb92946478057c04b034d17
○ Oral Factor D inhibitor - BCX9930 BCX9930 is a novel, oral, potent and selective small molecule inhibitor of Factor D currently in Phase 1 clinical development for the treatment of complement-mediated diseases. The 3rd of August 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for oral Factor D inhibitor, BCX9930. Staff excitement Staff team from Biocryst Pharmaceuticals, Inc seem to be really positive and excited about the incoming future of BCX9930. Such excitement has been seen in the last conference calls where staff members such as the CEO Jon P.Stonehouse, or the Vice President, William P.Sheridan would say the following words. “Embarrassment of riches”. “We agree with Alexion that creating a potent specific and great oral Factor D inhibitor is a great challenge, and we are happy we have one” , “My only concern is i have no concerns”, “Pipeline in a molecule”, “My aim is to make c5 inhibitors obsolete”, “This is Big”. Efficacy level The key for efficacy with this kind of treatment is improving the number of Hb Hemoglobin levels. BCX9930 showed 3.8g/dL improvement ( page 31 ). The competence, Novartis showed 2.87g/dL improvement and Alexion 2.4-2.6g/dL. https://preview.redd.it/5ow4oubsi1g61.png?width=1263&format=png&auto=webp&s=ef9f8339a593661c4741108fd09128ccfe0316e2 On December the 6th, 2020 BCX9930 data was released showing high potency and specificity for alternative pathway complement. “BCX9930 monotherapy has the potential to inhibit both intravascular and extravascular hemolysis”, “In the study, BCX9930 was highly specific for the alternative pathway and, after oral dosing of BCX9930 in primates, alternative pathway activity was completely suppressed.” “These data demonstrate that BCX9930 is a highly potent and specific orally bioavailable Factor D inhibitor with potential for treatment of patients with PNH and other alternative pathway mediated diseases,” said Dr. William Sheridan” Alternative Pathway What makes BCX9930 be a game changer, is the wide spectrum of Alternative Pathway Dysregulation disease it can treat. It can treat up to 8 diseases (page 26) as of now, that is why insiders call it “Pipeline in a molecule”. The diseases it treats are the following ones. https://preview.redd.it/hir48l0ti1g61.png?width=1273&format=png&auto=webp&s=36a8ee0c49df7d8d5fc1ca9a2c928f756430a6ef PNH (Paroxysmal nocturnal hemoglobinuria) aHUS (Atypical hemolytic uremic syndrome) ANCA vasculitis (antineutrophil cytoplasmic antibody-associated vasculitis) Lupus Nephritis IgAN vasculitis C3G (Glomerulonephritis) PMN (Primary membranous nephropathy) IgAN (IgA nephropathy) Potential market size by 2025 Assuming BCX9930 will be approved by 2025, and it will be able to treat those diseases, we reach the following conclusion. The potential market size BCX9930 will be aiming for by 2025 scores up to 44.53B/year. Being that number obtained summing up the following ones. “"PNH Treatment Market Size Worth $5.8 Billion by 2025" “"The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025" “"aHUS, having in mind the disease prevalence (2 and 5.5)/MM, and the disease being treated with Soliris - 500,000$/ year. The worldwide market size should range between ( $7.5B and $20.5B)" We take 7.5B as conservative. “"Vasculitis treatment market size forecast to reach $743.2M by 2025" “"IgAN, having in mind the 1/3,707 incidence rate, and the yearly cost of the drug $12,456 we are aiming for a market size of $4,660,088,544" “"Having in mind C3G can be treated with Soliris and it costs $500,000 a year. Summing up all those 45,700 patients the market size we aim for is 22.85B" All this data can be more detailedly found in the following google sheet mentioned before. Alexion buy out On December the 12th, 2020 Alexion announced that AstraZeneca was going to buy them for 39B. More than 90% of their revenue comes from their “Factor D” C5 inhibitor, being that the main reason why AstraZeneca wanted that buy out to happen. You might think, why does this matter?. Well, remember we have a Factor D which has shown to be more effective than Alexion’s, and is able to treat more diseases than they do aswell. This buy out reflects how undervalued BCX9930 is. Apart from the buy out, i think it's essential to mention that Alexion bought Achillion's factor D when it was in ph 2 for $930MM. In 2019 Alexion's SOLIRIS® (eculizumab) net product sales were $3,946.4 million. Soliris is currently approved to treat PNH adn aHUS. Have in mind BCX9930 is able to treat 6 diseases more, aimming for a wider market size, and also having greater efficacy/safety. Using a biotech mid-cap x7 revenue multiplier 3,964B = 27,748B. meanning a SP value of $157.56 for BCRX. I want to make clear again that BCX9930 is said to be best in-class treatment and it's able to treat more diseases, this numbers could go much higher. Phase II study Despite the company not PR'ing the start of the phase II study of BCX9930, the official page of clinacal trials, show that the start of phase II study was December the 18th, 2020. This is extremely bullish since it reasures our thoughts that Ph I data readout will be good and enough to keep the study going. https://preview.redd.it/9nbz3y6ui1g61.png?width=1509&format=png&auto=webp&s=77833ece74cc7adfb5797de905b3db239b6ae214 BCX9930 valuation Having in mind BCX9930 is a potential best-in-class treatment, Alexion got bought out for 39B mainly for their “Factor D” c5 inhibitor and the yearly market size it aims for in 2025 rounds 44.53B. BCX9930 valuation can not be less than a 30% of Alexion’s buy out price, this is 11.7B meaning 66.44$. I want to make clear that once the drug is approved and generating revenue, the average x7 revenue can be used, making it much more valuable than it’s now. Do not forget data readout is due Q1. https://preview.redd.it/gw1389xui1g61.jpg?width=1280&format=pjpg&auto=webp&s=3a0071d67a1f1513b05c9a0055bc355d20643085
Since Denner opened his position in Alexion, it took him 5 months to close the buy out deal, as shown in the picture below https://preview.redd.it/bh8cf54xi1g61.png?width=1300&format=png&auto=webp&s=a0f29d8baac51da14e88f333bd8271e43618ef81 After this exhaustive analysis on the company, we can easily acknowledge that BCRX is more than an strong BO candidate. A buy out coming from BIIB, company where Denner forms part of the BOD board of directors, would make total sense in the following 2 years once BCX9930 Factor D phase II data is unveiled.
This company could be the perfect example to have an idea of what we could expect from Biocryst's performance. From 2007 to 2014 Alexion's stock price grew a 1777%. Being valued at 10.5$ in 2007 and 186.6$ in 2014. Revenue generated by Alexion gradually grew up as their Factor D was approved to treat additional diseases, and the market size they captured got wider.
Biocryst Pharmaceuticals stock managing to do the SP move Alexion did, is more than doable with the unique pipeline it has. Having in mind Alexion made 66.4 MM revenue the first year while BCRX at least expects to generate 500 MM with Orladeyo, apart from it, additional revenue generated by Rapivab/Galidesivir stockpillings. Incoming Earning Reports are meant to be potential catalysts for the company, gradually becoming more meaningful as the market size they capture with Orladeyo becomes wider.
Jon Stonehouse CEO, also confirmed that the company will not need to do offerings anymore. The fact that the company is already generating revenue with Orladeyo is another strong evidence that confirms money risings will not be needed anymore.
Once the given information on the company is aknowledged, realizing how heavily the company has been manipulated by institutions, constantly making short pressure bigger in order to move the stock into ridiculous price levels, to be able to accumulate more shares at premium prices. Should not be of anyone's surprise, as this is a true "Embarrasment of Riches", like insiders call it, and they aim to load as much as thay can, at the very best premium prices. Total value: 184.77$ SP |
I've noticed destiny rarely talks about Africa, even when mentioning international relations. Africa is a large and complex to understand, but an important region of the world none the less. So if he's ever wanted to understand more about African, from Africa in the Cold War to African corruption and the African Continental Free Trade Area (AfCFTA), which is a free trade agreement that makes Africa one of the largest single markets in the world with 1.3 billion people across 55 countries and a combined (GDP) valued at US$3.4 trillion. (World Bank), this post may help. submitted by Elom-Abbey to Destiny [link] [comments] I hope this can be a useful guide to Destiny or anyone who is interested.
Part 1: The Cold War in Africa. The decolonisation of Africa happened post WW2 within the context of the Cold War. After the second world war, the major imperial powers were bankrupt and broken, and the new global superpowers (USA & Soviet Union) were both against empire for ideological and geopolitical reasons. This led to the superpowers exerting pressure on the Europeans to decolonise and left the two superpowers scrambling to exert influence in these new nations and bring them into their respective spheres of influence. This caused many of the post-colonial wars in Africa from in Angola to Ethiopia and Somalia as well as many more these were all a part of the power struggle between the communist and capitalist powers. The fall of the Soviet Union and China’s capitalistic reforms in the 1980’s-90's brought an end to the cold war and removed the need for the ideological superpowers to support proxy wars to expand their spheres of influence. Russia completely withdrew from Africa by 2000 and not long after 9/11 happened, shifting America (and by extension, the wests) attention to the middle east making Africa politically irrelevant to the west. Part 2: Africa's geography. African Population Clusters. Population Distribution of Africa Africa Divided Africa is big, but due to various geographic features Africa's populations is clustered into distinct zones that developed fairly independently of one another throughout history. we understand the cultural, historic, political differences between north Africa and SS-Africa but often overlook the equally profound differences between west Africa and east. Here is a very simplistic map of pre-colonial Africa the excludes the Swahili states along the eastern section of the continent. Before colonialism the West African Zone had more contact with north African and Europe than the Eastern African Zones and the East African zone had more contact with Asia by sea than they did with the west. This dynamic is hard to overcome even with modern infrastructure, but internally integrating the individual population clusters offers great hope for developing the continent on a regional basis, before attempting to integrate across the continent. This is how the African Union functions and the African Continental Free Trade Area is set to promote this. Part 3: African Continental Free Trade Area. Most countries trade with their neighbours. Inter-European trade sits at around 75%. Inter-American and Inter-Asian trade sits at around 60% source. Inter-African trade is 15-17%. African countries still have colonial economies that rely on digging raw material from the ground to send to the outside world to refine into manufactured goods to sell back to African countries at a tremendous mark up. Now the answers to this might seem easy. Trade more with your neighbour and move up the value chain. That is where the African Continental Free Trade Area come in. The AfCFTA makes Africa one of the largest single markets in the world with 1.3 billion people across 55 countries and a combined gross domestic product (GDP) valued at US$3.4 trillion. (World Bank). The Afcfta is the collimation of about 4 decades of work by African leaders to deal with the economic effects of colonialism. It presents the opportunity for African countries to bring 30 million people out of extreme poverty and to raise the incomes of 68 million others who live on less than $5.50 per day. It will boost Africa’s income by $450 billion by 2035 while adding $76 billion to the income of the rest of the world. Increase Africa’s exports by $560 billion, mostly in manufacturing and spur larger wage gains for women (10.5 percent) as well as reduce instability and insurgency by providing jobs to youth most susceptible to join radical groups. This is set to fuel a hybrid form of Import-Substitution Industrialization (ISI) by which there are no tariffs between African countries but high tariffs on goods from outside the continent/free trade zone. This is expected to boost industrialization in select African countries and spur market innovations by allowing African nations to trade freely and specialise in what they trade best in, while also protecting African industries from dumping and other forms of economic manipulation from outside powers. The AfCFTA faces its hurdles, but came into force last year and remains one of the biggest steps forward Africa has seen in decades. Part 4: The myth of African corruption Corruption exists in Africa. But the image that exists of a kleptocratic continent filled with failed states run by rabid warlords and jihadi's is a myth derived from the old colonial mentality of the "Negro being unbale to govern a nation." While corruption exists in Africa, corruption is not unique to Africa, nor is there is anything unique about African corruption. But to further prove this point according to the Global corruption index by Transparcy International: Botswana is LESS corrupt this Israel and is next to Spain on the index. Rwanda is LESS corrupt than Italy or Malta. Namibia is LESS corrupt than Greece. Senegal is LESS corrupt than Bulgaria. South Africa is AS corrupts is Romania and is the LEAST corrupt country in BRICS (Brazil, Russia, India, China, S. Africa) Ghana is LESS corrupt than Argentina or China. Benin and Burkina Faso are less corrupt than India. Ethiopia is TIED for corruption with Brazil (each rank at 94th) and both are far less corrupt than Vietnam, Thailand, Philippines etc. Kenya is LESS corrupt than Mexico. Russia is MORE corrupt than Egypt of Mali. Cameroon is LESS corrupt than Iran. Nigeria is TIED with Iran for corruption (both at 149). Congo is LESS corrupt than North Korea Sudan is Less corrupt than Venezuela. South Sudan, Somalia, Syria and Yemen rank as the combat corrupt countries in the world. This list includes samples from the most corrupt nations in Africa (South Sudan) to the least Rwanda and Botswana and contain roughly 60-70% of Africa's population Each of them is a level of corruption that is comparable to countries outside of Africa, from the most corrupt countries of Somalia and South Sudan being comparable to Asian countries like Yemen and North Korea according to the index and the least corrupt being comparable to some European nations. My only claim is the corruption in Africa is comparable to corruption in other parts of the world and the transparency international data supports that claim from the most to the least corrupt countries. There are clear double standards in how western media and culture talks about Ethiopian corruption compared to Russian corruption or Senegalese corruption compared to Bulgarian corruption. Corruption is a problem but people who write off every African country, politician or political initiative as doomed to fail due to corruption are engaging a racist double standard that Asia South America and Europe are not held to. I was going to cover some other topics, but this post is already long enough, but if this was interesting to you or you found this to be a useful guide, let me know and I will happily make another post breaking down:
Edit I’m glad people found this useful! This is part of some research I’ve been doing for a different project, but I thought this sub may find it interesting. I’ve seen interest for other posts so I may make others the future with my next post being on & Why some have dealt with post colonialism better than others. Ethiopia vs Nigeria. Ghana vs Ivory Coast, Rwanda vs south Sudan, Botswana vs Zimbabwe. |
Listen up retards. Do you happen to feel regret because you always think “ohhh if I yoloed my savings on TSLA/AMD/NVDA 🚀 leaps years ago I could be rich by now!!!” submitted by Audacimmus to wallstreetbets [link] [comments] Well if you didn't know already, it doesn’t really matter what happened in the past. Hindsight will always be 20/20. You shouldn’t be harsh on yourself on your past self that your past self wasn’t retarded enough to yolo their savings into AMD/TSLA/.... Your past self doesn’t have the same knowledge that your current self has. It’s fine. If you judged those stocks with the best DD you could do at the time and didn’t think they were worth it, then you did a good job. If you always think about what you could/should have done in the past, then you don't have the right attitude to play the stock market casino imho. The single most important thing is to be able to look ahead. There are always plenty of opportunities around. There are thousands of rockets that are still on earth right now. Some may depart this year, others will stay a little longer on earth. The true strength lies in being able to identify those rockets with the knowledge you have right now. And if you still miss most rockets that will take-off this year that's fine, maybe you'll learn, get better and you'll do better next year. Now, what if I told you there’s a big rocket that’s parked right right here on earth and it has decent chance for take-off this year? Maybe it won't quite reach the moon this year yet, but hey leaving the exosphere should already be a cool milestone. It has rock-solid fundamentals and will see lots of growth in the following years/decade. It’s a company that has the fundamental technology to power all the computer vision tech, which is bound to boom this decade. The company we’re talking about is of course Sony, and it is extremely undervalued right now. Its P/E is only 14. They have a P/S of 1.65, a PEG of 0.92 (< 2 is already somewhat exceptional for a company/conglomerate of Sony’s size, under 1 is a steal) Much lower than all of its same-sector peers. This indicates significant undervaluation. Next up Sony has a P/CF 13.2, ROE of 20% (S&P 500 average is 14% which would already be considered pretty good. 20% ROE is excellent), PEGY of 0.89, P/B of 2.65 and finally Sony has $41.6B in cash on hand. This makes Sony one of the cheapest tech/entertainment/EV/semiconductor growth stocks you will find on the market. (ROE of 20% + PEGY of 0.89 + PEG of 0.92 means this company is a growth stock based on the numbers alone, but we’ll dig into the actual company and overall outlook in a moment) I challenge all retards to find a company with similar benchmarks in one of the mentioned sectors, seriously. Quite frankly doing this DD honestly blew my mind. I kept looking everywhere for reasons why the company could be so undervalued and why they may struggle in the future. Very important to look at all the challenges the company faces to make sure I’m not just doing confirmation bias DD. But all I could find was the opposite. After several weeks and months of working on this DD, I can only conclude that it is overall a very solid company for a bargain price. The new CEO is taking the company in a great direction imho and I'm begin to think he could be Sony's Satya Nadella. So if you want some easy tendies, maybe consider $SNE while it is still cheap, I’d say. For the autists out there who care about analyst ratings, SONY ($SNE) currently has 18 BUY ratings, 2 OVERWEIGHT, 4 HOLD and 0 SELL. (= analyst consensus is a STRONG BUY). Very little analysts cover this stock compared to other entertainment/tech companies, so this adds to my assertion that the stock is very much under the radar. Which means you have time to get in before it gets noticed by the larger investing world and before it starts to get a more fair valuation (P/E of around 30 would be more fair for this company I think, but still cheaper than many same sector peers). But, anyway the few analysts who do happen to cover this company are basically all saying it’s an instant-buy at its current price. Most boomer investors still think big Japanese tech companies are dinosaurs that have long been surpassed by China, South Korea and Apple etc ages ago. Young boomers may think Sony = PlayStation and that it's it. But the truth is that PlayStation, while very important (about 24% of Sony's total revenue last year), is a part of a larger story. Lots of investors in general associate Sony with the passé Japanese electronics companies from the 80’s and the 90’s. Just like a lot people may think BlackBerry is a struggling phone company. While Sony may not be the powerhouse in consumer electronics it was in the 80’s and the 90’s, in a lot of ways they are more relevant than ever before. Despite being a well-known brand and being known as the company behind PlayStation, for some reason its stock still seems to be under the radar among both retail and institutional investors. And boy, are they mind-blowingly undervalued. Even if a big part of its business would collapse tomorrow, they would still be slightly undervalued. And I am about to tell you why. (& btw compared to Japanese tech/entertainment stocks $SNE is still super cheap (Canon, Nikon, Toshiba, Sharp, Panasonic, Square Enix, Capcom, Nintendo, Fujitsu all have P/E ratios ranging from 18 to 77 and none of them have the combination of global clout, fundamentals & growth prospects that Sony has)) 2021 Sony as a corparation is not the fucking Sony from 2005-2015’s, just like BlackBerry in 2021 is not the fucking Blackberry from 2012. Just like Garmin in 2021 is not Garmin from 2011. Just like AMD in 2021 is not AMD from 2012. No, in 2021, Sony is the global leader in imaging technology and people do not fucking realize it. Sony has 50% marketshare in the CMOS image sensor market. There’s a very good chance the smartphone in your pocket has Sony image sensors (unless it’s a Samsung phone). Sony image sensors are powering a big part of today's vision/camera technology. And they will power even more of tomorrow's computer vision tech. In 2021, Sony is a behemoth in video games, music, anime, movies and TV show production. Sony is present in every segment of entertainment. Sony’s entertainment branches have been doing great business over the past 5 years, especially music and PlayStation. Additionally, Sony Pictures has completely turned around. In 2021, Sony is the world’s biggest music publisher (and second biggest music company overall). Music streaming has been a boon for Sony Music and will continue to be. In 2021, Sony is among the biggest mobile gaming companies in the world (yes, you read that right). And it’s mainly thanks to one game (Fate/Grand Order) that nets them over $1B revenue each year. One of the biggest mobile gaming companies + arguably biggest gaming brand in the world (PlayStation). In 2021, Sony is an EV company. They surprised the world when they revealed their “Vision-S” at CES 2020. At the reception was fantastic. It is seriously one of the best looking EV’s. They already sell sensors to Toyota. Sony will most like sell the Vision-S's tech to other car manufacturers (sensors for driving assistence / autonomous driving, LiDAR tech, infotainment system). 40 sensors in the Sony Vision-S Considering the overwhelmingly good reception of the Vision-S so far, I suspect the Vision-S could be another catalyst that will put Sony as a company on the radar of investors and consumers. We've seen insane investment hype for anything even remotely related to EV over the past year. We've seen a company that barely had a few EV design concepts (oh wait, they had a gravity-powered truck though) even get a $30B market cap at some point lmao. But somehow a profitable company ($SNE) that has an EV that you can actually drive, doesn't even have a fair valuation? In 2020’s Sony’s brand value is at their highest point since 12 years. In 2021, it is projected to be a its highest point since 2001 assuming same growth as average yearly growth from 2015 to 2020. Keep in mind brand valuation is a bit bullshitty as there’s no standardization to compare brands from different sectors, let alone non-consumer-facing brands with consumer-facing brands. But one thing we can note is that Sony both as B2C brand and as a B2B company is on a big upwards trend. https://interbrand.com/best-global-brands/sony/ https://careers.uw.edu/blog/2020/03/17/these-are-the-10-biggest-video-game-companies-in-north-america-shared-article-from-zippia/ In 2021, Sony is an entertainment behemoth. They have grown their entertainment branches by a huge amount over the past 5 to 10 years (they made some big acquisitions in the music space especially and they’re now also all-in in anime). I don’t think people realize how big Sony is as an entertainment company. I dug up the numbers and as of Q3 2020, PlayStation is the second biggest video game company in the world (Tencent is #1) in revenue (I suspect Sony might dethrone Tencent after Sony’s FY Q3 2020 is released). But Sony already comes very close to Tencent especially if you add Fate/Grand Order (which is under Sony Music and not under PlayStation) under PlayStation. There’s no single other company that has this unique combination of a dominant/important position in all entertainment segments. (video games + music + movies + TV series + anime + TV networks). I guess Tencent maybe? In 2021, Sony has amazing momentum in the camera space. If you’re familiar with the enthusiast photography space, you should know this. Basically, the market is slowly shifting from SLR to mirrorless cameras. This is because mirrorless cameras tend to smallelighter, have faster AF, better low light performance, better battery life and better video performance. Sony is the company that has been specializing in the development for mirrorless cameras for over a decade while Canon’s bread and butter has always been SLR cameras. Sony is in the lead when it comes to mirrorless cameras and that’s where the market is shifting towards. Because the advantages of mirrorless have become more and more apparent and Sony’s cameras have become technically superior, Sony has gained quite a bit of market share over Canon and Nikon in the last few years. In 2019, Sony overtook Nikon as the #2 camera manufacturer. Sony is in an upwards trend here. (they have the ambition to become the world’s #1 camera brand) Sony also has very good marketing for their cameras. (Sony has a lot of YouTubers / influencers / brand ambassadors for their cameras despite being a smaller brand than Canon) (just search on YouTube and/or Google “switching to Sony from Canon” just to give you an idea that they do have amazing brand momentum in the camera space. You won’t get as many hits for the opposite) A huge portion of Sony’s profit comes from image sensors in addition to music and video games. This is in addition to their highly profitable financial holdings division & their more moderately profitable electronics division. Sony’s electronics division, unlike other Japanese brands, has shown great resilience against the very strong competition from China & South Korea. They have been able to maintain their position in the audio space and as of 2020 are still the global market leader in high-end TV’s (a position they have been holding for decades) and it seems they will continue to be able to maintain that. But seriously this company is dirt-cheap compared to any of its peers in any segment and there’s various huge growth prospects for Sony:
PS+ growth and software digital ratio growth
Sony Entertainment While Netflix, Disney, AT&T, Amazon, and Apple are waging the great streaming war, Sony has been quietly building its anime streaming empire over the past years.
Anime growth “The global size is expected to reach USD 36.26 billion by 2025, registering a CAGR of 8.8% over the forecast period, according to a study conducted by Grand View Research, Inc. Growing popularity and sales of Japanese anime content across the globe apart from Japan is driving the growth” (tl;dr anime 🚀🚀🚀🚀🚀, Sony is all in on anime and they have pretty much no competition) Anime is the fastest growing subsegment of movies/video entertainment worldwide.
Sony Music Entertainment Japan Aniplex
US video game market growth (worldwide growth has a 13% CAGR) PlayStation revenue and operating profit growth
But so far the tl;dr Image sensors: 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 IoT/Industry 4.0 chipsets: 🚀🚀🚀🚀🚀🚀🚀 PS5/PSN/PS+: 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 Online medical services (M3 inc.): 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 Anime: 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 Fate/Grand Order: 🚀🚀🚀🚀🚀 Demon Slayer: Mugen Train 🚀🚀🚀🚀🚀 Sony Music / music streaming (the performance of Sony Music’s in Sony’s business is seriously understated. The numbers speak for themselves): 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 Sony Electronics 🚀 Sony Financial Holdings (very stable & profitable business, even managed to grow slightly during pandemic when most insurance companies performed more poorly): 🚀🚀🚀 Still have to cover Sony Pictures, but their upcoming movie slate looks pretty good honestly (Spider-Man sequel, Venom: Let There Be Darkness, Ghostbusters: Afterlife, Uncharted, Morbius, Hotel Transylvania 4 so that's worth one rocket as well imho 🚀 tl;dr of tl;dr: 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 Disclaimer: I am not a financial advisor. I am an idiot that's trying to understand why $SNE stock is so cheap. Positions: SNE 105C 21st January 22 |
submitted by GriffinFTW to TNOmod [link] [comments] https://preview.redd.it/1hd6ffiujzf61.png?width=1204&format=png&auto=webp&s=eb19562c8596e7fffa529a9ffcb124fa8f5eaa35 By deviantART user Rus-Storm. Here's the description of this scenario (copied from the author's notes): This world in translation from Japanese to Russian is called "The New Order: Last Days of Asia." Why is it so? That’s because the main world scarecrow is the Japanese Empire, which dominates the Pacific Ocean, East Asia, Indochina, Australia, Oceania and Central America. Germany did not attack Soviet Russia, as a result of which it became the hegemon of Europe. And Russia adopted a plan of autonomization ... But first things first. |
South Koreans: “Peace is what we need” Two countries, one people - no peace. There is still no official peace between North and South Korea, despite the Korean War ending more than 60 years ago. Despite a similar geographical size, South Korea's population (over 51 million) is almost twice as large as North Korea's (more than 25 million). Due to their poor diet, North Koreans tend to be... The key difference between North Korea and South Korea is that North Korea has a Communist Dictatorial form of government while South Korea has a Republican form of government. North Korea and South Korea are the two countries that reside in the Korean Peninsula. Originally Korea was a single empire, under the rule of Japan until August 15, 1945, when both these countries gained independence. However, later, the Korean peninsula divided into two countries after the WWII when North Both North and South had to recover, but they would do so under different political structures. At the end of WWII, the U.S. essentially appointed the anti-communist leader Syngman Rhee to rule South Korea. The South declared itself a nation in May 1948. Rhee was formally installed as the first president in August and immediately began waging a low-level war against communists and other The political differences between the two rival states led to the outbreak of war in 1950, when North Korea invaded South Korea. The war lasted three years but North Korea and South Korea have... well i totally agree with yur question. I would like to answer it with few basics like where is North Korea and hows its geographical position determine its current situation. Where is North Korea? North Korea is a country situated next to China. North Korea's antics could easily spin out of control in different directions. A South Korean over-reaction, either in the direction of concessions to Pyongyang or a military response to North This universe is so huge. Every country is unique with its culture and tradition. However, there will always be lot of variations between northern culture and southern culture. Here I am talking about North Korea and South Korea. Yes, there is a huge difference between North Korea and South Korea in a very weird sense. Before you plan to visit, make sure you know these 10 major differences North and South Korea have been divided for more than 70 years, ever since the Korean Peninsula became an unexpected casualty of the escalating Cold War between two rival superpowers: the Soviet Why So Many Esports Pros Come From South Korea If there’s a competitive mode, you'll find Korean players at the top of the charts. But the reasons have less to do with esports and more to do
[index] [8288] [4526] [8038] [6126] [7714] [2270] [249] [5671] [188] [1505]
Try out ThePremium Network for free https://goo.gl/ocKVLaSubscribe: https://goo.gl/Hnoaw3-----... Whatever you need a website for, create yours today with Wix: https://www.wix.com/go/infographics Why did North Korea and South Korea split?SUBSCRIBE TO US -... A video explaining why the country of Korea split into two different countries: North Korea and South Korea. In 1945, Korea was divided into South Korea and North Korea. Despite the fact that communist North Korea and democratic South Korea are neighbors, the life i... UPDATE. A year after publishing this video, I decided to make another video that explains why it might not be a good idea to travel to North Korea yourself: ... Who Are North Korea's Allies? https://www.youtube.com/watch?v=zYi9vAI7weA» Subscribe to NowThis World: http://go.nowth.is/World_SubscribeKnown as the hermit ... As COVID-19 spreads around the world, some countries' timelines look different from others. With a combination of contact tracing, testing, and isolating cas... top 10 amazing facts about north korea and south korea you need to knowSubscribe to our channel: ... top 10 amazing facts about north korea and south korea you need to knowSubscribe to our channel From space, the difference between North and South Korea is drastic. In video released by NASA that was taken from the International Space Station, North Kor... Subscribe to our channel: http://bit.ly/FactsVerse Image Credits :
Copyright © 2024 m.bk0info.site